English Spanish Chinese Russian French Japanese Portuguese Hindi Telugu Tamil

Zeitschrift für Biomedizinische Wissenschaften

  • ISSN: 2254-609X
  • H-Index der Zeitschrift: 15
  • Zitierbewertung der Zeitschrift: 5.60
  • Journal-Impact-Faktor: 4.85
Indiziert in
  • Genamics JournalSeek
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • Verzeichnis der Indexierung von Forschungszeitschriften (DRJI)
  • OCLC – WorldCat
  • Google Scholar
  • SHERPA ROMEO
  • Geheime Suchmaschinenlabore
Mehr sehen
Teile diese Seite

Abstrakt

Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance

Dae Won Kim, Marc Uemura and Adi Diab

Since pembrolizumab (Keytruda®) was approved for advanced melanoma in September 2014, multiple PD-1 blockade agents have been explored in other malignancies. Emerging clinical data has demonstrated durable clinical activity and safety of PD-1/L1 blockade agents in diverse cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial cancer, Hodgkin lymphoma, and head and neck cancer. Thus, PD-1/L1 blockade agents have led to a paradigm shift in cancer therapy. In this review, current indications of PD-1 blockade agents in advanced solid malignancies will be discussed.